Butamax Advanced Biofuels LLC, has been granted patent number 8,129,162 for production of iso-butanol from biological resources.

This latest patent was issued from a series of applications covering modified KARI enzymes that optimize production of biobutanol by Butamax’s proprietary microorganisms. These microorganisms are engineered with the isobutanol biosynthetic pathway invented by Butamax that includes five enzymatic steps that convert sugar to isobutanol. The KARI enzyme performs the second step of the pathway which is fundamental to achieving high biobutanol yield. This latest invention is essential to best cost of manufacture position.

Since 2003, the Butamax team has pioneered new technology innovations in order to offer the most cost-effective production of biobutanol for the transportation fuels market. The company will continue its commitment to innovation in the areas of biocatalyst, engineering design and end-use applications to deliver maximum value to licensees.

“With these new KARI enzymes, we have achieved a significant improvement in performance, which is necessary for low-cost commercial production of biobutanol,” said Paul Beckwith, Butamax CEO. “We are pleased that our research team continues to be recognized for their innovation in biobutanol technology. Their work has led to the only cost-effective retrofit option that enables existing ethanol manufacturers to produce drop-in biofuels.”